Literature DB >> 6872943

Antiestrogenic effects of LY 117018 in MCF-7 cells.

S M Scholl, K K Huff, M E Lippman.   

Abstract

LY 117018 is a nonsteroidal compound which has been shown to antagonize more effectively than tamoxifen the effects of estradiol in rats and mice. We have further defined the properties of this compound on cell growth and progesterone receptor (PR) induction and have compared inhibitory effects to relative binding affinity in a human breast cancer cell line. In MCF-7 cells, LY 117018 [( 6-hydroxy-2-(p-hydroxyphenyl)-benzo(b) thien-3-yl-p-(2-(pyrrolidinyl)ethoxy phenyl ketone] is devoid of estrogenic effects, has a greater affinity for the estrogen receptor (ER) than tamoxifen at 4 C, and is 100-1000 times more potent than tamoxifen at inhibiting cell growth. While tamoxifen has been reported to induce PR, a purported estrogen effect, the LY 117018 compound failed to induce PR using a broad range of concentrations. The direct antagonistic effect of LY 117018 was demonstrated by the use of varying concentrations of LY 117018 and estradiol concomitantly. We conclude that LY 117018 is a very effective antiestrogen devoid of any stimulatory effects among these parameters tested.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6872943     DOI: 10.1210/endo-113-2-611

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  Synthesis of dihydronaphthalene analogues inspired by combretastatin A-4 and their biological evaluation as anticancer agents.

Authors:  Casey J Maguire; Zhi Chen; Vani P Mocharla; Madhavi Sriram; Tracy E Strecker; Ernest Hamel; Heling Zhou; Ramona Lopez; Yifan Wang; Ralph P Mason; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney
Journal:  Medchemcomm       Date:  2018-08-24       Impact factor: 3.597

2.  Anti-proliferative effects of 1,2-diphenylethane oestrogens and anti-oestrogens on human breast cancer cells.

Authors:  R W Hartmann; T Sinchai; G Kranzfelder
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

3.  Studies on the mammary tumor-inhibiting effects of diethylstilbestrol and its mono- and diphosphate.

Authors:  M R Schneider; E von Angerer; J Prekajac; W P Brade
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

4.  The inhibitory effect of 4-chloro-2-(2,6-dichloro-4-hydroxyphenyl)-1-ethyl-6-hydroxyindole (D 15413) on estrogen-dependent mammary tumors.

Authors:  E von Angerer; J Prekajac; M R Schneider; M R Berger
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

5.  A new triphenylethylene compound, Fc-1157a. II. Antitumor effects.

Authors:  L Kangas; A L Nieminen; G Blanco; M Grönroos; S Kallio; A Karjalainen; M Perilä; M Södervall; R Toivola
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro.

Authors:  Klaus H Baumann; Elmar Klusmeier; Isabel Eggemann; Silke Reinartz; Achim Almeroth; Mathias Kalder; Uwe Wagner
Journal:  Breast Cancer (Auckl)       Date:  2009-04-07

7.  Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts.

Authors:  P Pace; M Jarman; D Phillips; A Hewer; J Bliss; R C Coombes
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Parathyroid hormone-related protein secretion is inhibited by oestradiol and stimulated by antioestrogens in KPL-3C human breast cancer cells.

Authors:  J Kurebayashi; H Sonoo
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  A new human breast cancer cell line, KPL-1 secretes tumour-associated antigens and grows rapidly in female athymic nude mice.

Authors:  J Kurebayashi; M Kurosumi; H Sonoo
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.